Spots Global Cancer Trial Database for programmed cell death protein 1 inhibitor
Every month we try and update this database with for programmed cell death protein 1 inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC | NCT06364046 | Carcinoma Small Cell Lung... | Drug-eluting be... Serplulimab Intravenous che... | 18 Years - | The Central Hospital of Lishui City | |
| Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma | NCT06342167 | Locally Advance... Sintilimab Radiotherapy Concurrent Chem... Immunonutrition | Radiotherapy Programmed Cell... Immunonutrition... | 18 Years - 80 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC | NCT06364046 | Carcinoma Small Cell Lung... | Drug-eluting be... Serplulimab Intravenous che... | 18 Years - | The Central Hospital of Lishui City | |
| Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma | NCT06342167 | Locally Advance... Sintilimab Radiotherapy Concurrent Chem... Immunonutrition | Radiotherapy Programmed Cell... Immunonutrition... | 18 Years - 80 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up | NCT05123287 | Plaque, Atheros... Immune Checkpoi... Programmed Cell... Carotid Artery ... Intimal Medial ... | PD-1 immune che... | 18 Years - 90 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure | NCT05248022 | Carcinoma, Non-... | Drug-eluting be... Programmed Cell... | 18 Years - | The Central Hospital of Lishui City | |
| Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation | NCT05975307 | Muscle-Invasive... Programmed Cell... Radiotherapy | Toripalimab Gemcitabine Cisplatin Carboplatin Intensity-modul... | 18 Years - 75 Years | Sun Yat-sen University | |
| Multi-center Observational Study on the Progression of Atherosclerotic Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up | NCT04922541 | Plaque, Atheros... Programmed Cell... | PD-1 inhibitor | 18 Years - 90 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure | NCT05248022 | Carcinoma, Non-... | Drug-eluting be... Programmed Cell... | 18 Years - | The Central Hospital of Lishui City | |
| Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma | NCT06342167 | Locally Advance... Sintilimab Radiotherapy Concurrent Chem... Immunonutrition | Radiotherapy Programmed Cell... Immunonutrition... | 18 Years - 80 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC | NCT06364046 | Carcinoma Small Cell Lung... | Drug-eluting be... Serplulimab Intravenous che... | 18 Years - | The Central Hospital of Lishui City |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
